Zealand Pharma A/S
CSE:ZEAL

Watchlist Manager
Zealand Pharma A/S Logo
Zealand Pharma A/S
CSE:ZEAL
Watchlist
Price: 600 DKK -0.33% Market Closed
Market Cap: 42.6B DKK

Intrinsic Value

The intrinsic value of one ZEAL stock under the Base Case scenario is 99.94 DKK. Compared to the current market price of 600 DKK, Zealand Pharma A/S is Overvalued by 83%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

ZEAL Intrinsic Value
99.94 DKK
Overvaluation 83%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation History
Zealand Pharma A/S

ZEAL
Valuation History
HIDDEN
Show
Valuation History Unavailable

Historical valuation for ZEAL cannot be conducted due to limitations such as insufficient data or other constraints.

Valuation In Progress...
Valuation In Progress...
0%

Fundamental Analysis

Zealand Pharma A/S
CSE:ZEAL
DK
Biotechnology
Market Cap
42.4B DKK
IPO
Nov 1, 2010
DK
Biotechnology
Market Cap
42.4B DKK
IPO
Nov 1, 2010
Price
krfalse
EPS
krfalse
Company Overview
Loading...
Business Segments
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
How do you feel about ZEAL?
Bearish
Neutral
Bullish
AI Assistant
AI Assistant
Ask me anything about Zealand Pharma A/S
Financials
Annual
Quarterly
TTM

Balance Sheet Decomposition
Zealand Pharma A/S

Current Assets 8.5B
Cash & Short-Term Investments 8.2B
Receivables 291m
Other Current Assets 10.7m
Non-Current Assets 977.9m
Long-Term Investments 819.6m
PP&E 125.2m
Intangibles 12.6m
Other Non-Current Assets 20.4m
Efficiency

Free Cash Flow Analysis
Zealand Pharma A/S

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Zealand Pharma A/S

Revenue
62.7m DKK
Cost of Revenue
-7.9m DKK
Gross Profit
54.8m DKK
Operating Expenses
-1.3B DKK
Operating Income
-1.3B DKK
Other Expenses
190.2m DKK
Net Income
-1.1B DKK
Fundamental Scores

ZEAL Profitability Score
Profitability Due Diligence

Zealand Pharma A/S's profitability score is 23/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Exceptional Revenue Growth Forecast
ROE is Increasing
Negative 1-Year Revenue Growth
23/100
Profitability
Score

Zealand Pharma A/S's profitability score is 23/100. The higher the profitability score, the more profitable the company is.

ZEAL Solvency Score
Solvency Due Diligence

Zealand Pharma A/S's solvency score is 75/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Negative Net Debt
75/100
Solvency
Score

Zealand Pharma A/S's solvency score is 75/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

ZEAL Price Targets Summary
Zealand Pharma A/S

Wall Street analysts forecast ZEAL stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ZEAL is 980.14 DKK with a low forecast of 757.5 DKK and a high forecast of 1 155 DKK.

Lowest
Price Target
757.5 DKK
26% Upside
Average
Price Target
980.14 DKK
63% Upside
Highest
Price Target
1 155 DKK
93% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Zealand Pharma A/S
does not pay dividends
Shareholder Yield

Current shareholder yield for ZEAL is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

ZEAL News

Other Videos
What is the Intrinsic Value of one ZEAL stock?

The intrinsic value of one ZEAL stock under the Base Case scenario is 99.94 DKK.

Is ZEAL stock undervalued or overvalued?

Compared to the current market price of 600 DKK, Zealand Pharma A/S is Overvalued by 83%.

Back to Top